Edith Cowan University Research Online

ECU Publications Post 2013

2015

# The relationship between the halosperm assay and semen analysis performed according to the 4th and 5th Editions of the World Health Organization guidelines

Ashleigh McEvoy Edith Cowan University, a.mcevoy@ecu.edu.au

Peter Roberts Edith Cowan University, p.roberts@ecu.edu.au

Kailin Yap

Phillip L. Matson Edith Cowan University, p.matson@ecu.edu.au

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013

Part of the Other Medical Sciences Commons

10.4172/2167-0250.1000127

This is an Author's Accepted Manuscript of: McEvoy, A., Roberts, P., Yap, K., & Matson, P. (2015). The relationship between the Halosperm Assay and semen analysis performed according to the 4th and 5th Editions of the World Health Organization guidelines. *Andrology*, 4(1). Available here This Journal Article is posted at Research Online.

https://ro.ecu.edu.au/ecuworkspost2013/1700



Open Access

# The Relationship between the Halosperm Assay and Semen Analysis Performed According to the 4<sup>th</sup> and the 5<sup>th</sup> Editions of the World Health Organization Guidelines

# Ashleigh McEvoy<sup>1,\*</sup>, Peter Roberts<sup>1</sup>, Kailin Yap<sup>2</sup> and Phillip Matson<sup>1</sup>

<sup>1</sup>Edith Cowan University, Joondalup 6027, Western Australia, Australia <sup>2</sup>Fertility North, Western Australia, Australia

#### Abstract

**Background:** As a standard reference to evaluate male factor infertility, the majority of fertility laboratories use the 4<sup>th</sup> or 5<sup>th</sup> Editions of the World Health Organization's semen analysis guidelines. Following the release of the 5<sup>th</sup> Edition, debate over its legitimacy has resulted in some laboratories using the 4<sup>th</sup> and others the 5<sup>th</sup> Edition. DNA integrity tests have been shown to be a valuable adjunct to semen analysis and have subsequently been adopted by many fertility laboratories. This study explored the prevalence of samples with high DNA fragmentation levels according to semen analysis categories using both the 4<sup>th</sup> and the 5<sup>th</sup> Edition reference ranges.

**Materials and Methods:** The study included 905 consecutive semen samples from 863 infertile couples attending a fertility clinic. A semen analysis was conducted according to both the 4<sup>th</sup> and 5<sup>th</sup> Edition guidelines published by the World Health Organization. DNA damage was assessed using the Halosperm G2 test kit and expressed as a percentage DNA fragmentation level.

**Results:** Alongside both the World Health Organization 4<sup>th</sup> and 5<sup>th</sup> Edition semen analysis criteria abnormal DNA fragmentation levels were more common in abnormal semen samples however elevated DNA fragmentation levels were also found in normal semen samples using the same criteria. Of the samples that were graded as normozoospermic according to the 5<sup>th</sup> Edition guidelines 16% were deemed to have elevated DNA fragmentation levels compared to 11.7% graded by the 4th Edition guidelines. The number of normozoospermic samples, graded according to the 5<sup>th</sup> Edition guidelines was significantly higher (n=697) than when the same samples were graded according to 4<sup>th</sup> Edition guidelines (n=385) (p=0.001). A significant proportion of samples with an abnormal DNA fragmentation level corresponding to the World Health Organisation 4th and 5th Edition criteria were evident in normozoospermic (p <0.05), normoteratozoospermic (p=<0.005) and normoasthenozoospermic (p<0.05) samples.

**Conclusion:** Our findings indicate that abnormal DNA fragmentation levels are proportionate to the World Health Organisation semen analysis criteria with fragmentation levels increasing according to the increasing number of semen analysis abnormalities. In some cases however, abnormal fragmentation levels were recorded when semen analysis was normal and normal fragmentation levels were recorded where the semen analysis was considered abnormal.

**Keywords:** DNA fragmentation; Halosperm; Semen analysis; WHO 4<sup>th</sup> Edition; WHO 5<sup>th</sup> Edition; Sperm; DNA damage

### Introduction

Traditionally, male infertility is diagnosed using World Health Organization (WHO) standard parameters which are published in a laboratory manual providing guidelines to laboratories for processing human semen and cut-off values to determine normality or abnormality [1]. Since publication of the first manual in 1980 there have been a number of updates released with the latest two editions being the 4th Edition in 1999 and the 5th Edition in 2010 [2]. Substantial changes between the two editions have resulted in the same patient being diagnosed (under the 5th Edition guidelines) with a normal semen analysis when they would have been diagnosed with an abnormal semen analysis had the laboratory used the previous version cut-off values. However, the application and reference values presented in the 4th Edition resulted from vague reference populations and therefore lacked transparency, resulting in little consensus around the accuracy of these values [3,4]. Furthermore this was acknowledged by the WHO [2,5]. Although the 5th Edition has included clearly defined reference ranges, concerns have been raised over the studies that generated these values [2] and so debate has ensued over its legitimacy leaving no definitive agreement between laboratories as to which edition should be used [6].

While semen analysis is regarded as a key tool to evaluate male infertility [4] in spite of which reference values are used [7] it does not consider sperm DNA integrity. DNA fragmentation testing whilst considered useful, has not yet been universally accepted due to a lack of standardization of tests and protocols [8].

Since about 15% of infertile men undergoing a semen analysis will have semen within normal parameters [9,10], there has been a focus on sperm DNA fragmentation and its association with infertility. Elevated levels of DNA fragmentation have been linked with infertile

\*Corresponding author: Ashleigh McEvoy, School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup 6027, Western Australia, Australia, Tel: +61-6304-3548; E-mail: a.mcevoy@ecu.edu.au

Received January 15, 2015; Accepted February 09, 2015; Published February 16, 2015

**Citation:** McEvoy A, Roberts P, Kailin Yap, Matson P (2015) The Relationship between the Halosperm Assay and Semen Analysis Performed According to the 4<sup>th</sup> and the 5<sup>th</sup> Editions of the World Health Organization Guidelines. Andrology 4: 127. doi:10.4172/2167-0250.1000127

**Copyright:** © 2015 McEvoy A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: McEvoy A, Roberts P, Kailin Yap, Matson P (2015) The Relationship between the Halosperm Assay and Semen Analysis Performed According to the 4<sup>th</sup> and the 5<sup>th</sup> Editions of the World Health Organization Guidelines. Andrology 4: 127. doi:10.4172/2167-0250.1000127

men [10-14], poor fertilization rates [15,16], specific semen defects [17], miscarriage and poor artificial reproductive technology results [18]. Furthermore, infertile men have been shown to have substantially higher levels of DNA fragmentation than fertile men [13] and hence DNA fragmentation testing has been proposed as a valuable adjunct to routine semen analysis when considering the fertility potential of a man [16].

Although DNA fragmentation testing can be conducted in a number of ways, the Halosperm assay has been described as a 'cheap and convenient' test [18] that has a relatively short and simple protocol with correlations having been observed with some of the most commonly recognised tests [11,19-21]. The aim of this study was to formally investigate the clinical significance of the Halosperm test and assess its relationship to the two most recent WHO semen analysis guidelines.

#### **Materials and Methods**

We studied 905 consecutive semen samples from 863 men who underwent semen analysis and DNA fragmentation testing using the Halosperm assay as part of their fertility treatment. The study was approved by the Edith Cowan University Human Research Ethics committee and the Joondalup Health Campus Human Ethics Committee.

#### Semen analysis

Men were instructed to have 2 to 5 days sexual abstinence before producing a semen sample for analysis. Semen samples were collected by masturbation into a clean 60 ml wide-mouthed universal container and processed within 1 hour of ejaculation and liquefaction. Semen analysis was performed according to the WHO 4<sup>th</sup> Edition guidelines [22] for volume, concentration, motility and morphology. Semen samples were then classified according to both WHO 4th and 5th Edition criteria [1] as shown in Table 1.

Following semen analysis, DNA fragmentation analysis was carried out using the Halosperm G2 test kit (Halotech DNA SL). Details of this procedure have been described elsewhere [23] but briefly, semen samples were mixed with a liquefied agarose gel and placed onto a pre-coated slide. The slides were refrigerated for 5 minutes before being treated with a denaturing agent, followed by a lysis solution and finally staining solutions. The criteria to determine fragmented and non-fragmented DNA was followed according to the manufacturer's instructions. In essence spermatozoa with a large or medium sized halo depict unfragmented DNA whilst those with either a small halo or without a halo and those with a weak or irregular stained core depict fragmented DNA. The DNA Fragmentation Levels (DFL) for each sample was assessed by counting a minimum of 300 sperm under the x100 objective of the microscope. The numbers of sperm judged to have fragmented DNA were expressed as a percentage of the total number. Samples with a reading of >30% were deemed abnormal.

#### **Statistical Analysis**

Pearson correlations and analysis by ANOVA were performed to study the relationship between sperm DNA fragmentation and semen analysis results with post-hoc testing by Tukey's HSD and proportions compared by a Chi-squared test. The minimum level of significance was set at P <0.05. Microsoft Excel and StatistiXL (Nedlands, Western Australia) statistical packages were used to perform all statistical analyses.

# Results

#### Semen quality according to different WHO criteria

Using the reference ranges in the WHO manual  $4^{th}$  Edition, 385/905 (42.5%) semen samples were classed as normozoospermic with the remainder having 1 or more abnormalities as shown in Table 2. However, classification of the same samples using the reference ranges provided in the WHO manual 5<sup>th</sup> Edition showed that 697/905 (77.0%) were said to be normozoospermic, simply as a consequence of lower limits of normality. Table 2 also shows that of the 520 samples with 1 or more abnormalities according to WHO 4th Edition, 78 (25%) had the same number when classisfied according to WHO 5th Edition and 442 (85%) had a reduction in the number of abnormalities.

#### Semen analysis and DNA fragmentation

A summary of the 905 semen analysis results and their correlation with the corresponding DNA fragmentation results is shown in Table 3. A significant positive correlation was seen between SDF and sexual abstinence (ie longer abstinence associated with higher SDF), whereas significant negative correlations (ie lower semen quality associated with higher SDF) were seen between SDF and sperm concentration, motility and morphology.

The mean DNA fragmentation results according to semen quality are shown in Table 4. The only statistically significant difference in DFLs between samples classified under the 4<sup>th</sup> and 5<sup>th</sup> Editions was for the normozoospermic samples. However, for both classification systems as shown in Table 4, there were significant increases in the DFLs as the severity of semen abnormalities increased.

Semen Parameters	WHO 4th Edition	WHO 5th Edition	
Volume (mL)	2	1.5	
Sperm Concentration (10 <sup>6</sup> /mL)	20	15	
Motility	50% (a + b)*	32% (a + b)*	
Morphology (% normal)	14	4	

\*Grade a=rapid progressive motility (>25  $\mu$ m/s), \*Grade b=slow/sluggish progressive motility (5-25  $\mu$ m/s).

 Table 1: WHO 4<sup>th</sup> Edition and WHO 5<sup>th</sup> Edition semen analysis criteria cut off values. (Adapted from Esteves, et al. [28]).

Abnormalities		WHO 5 <sup>th</sup> Edition				
		0	1	2	3	Total
WHO 4 <sup>th</sup> Edition	0	385	0	0	0	385
	1	233	46	0	0	279
	2	72	81	19	0	172
	3	7	25	24	13	69
	Total	697	152	43	13	905

**Table 2:** The number of abnormalities (sperm concentration, motility or morphology) in 905 semen samples when classified according to the reference ranges of WHO  $4^{th}$  and  $5^{th}$  Edition manuals.

Variable	Value	Pearson's r	P value
Abstinence (days ± SEM)	4.1 ± 0.2	0.11	0.001*
Volume (ml ± SEM)	3.5 ± 0.1	0.05	0.159
Sperm concentration (x10 <sup>6</sup> /ml ± SEM)	68.6 ± 2.2	-0.17	0.000*
Sperm motility (% ± SEM)	59.0 ± 0.6	-0.30	0.000*
Sperm morphology (% ± SEM)	14.0 ± 0.2	-0.24	0.000*

Values are presented as mean ± SEM.

\*Significant association.

 Table 3: Pearson Correlation for DNA fragmentation level to corresponding semen parameters, 905 samples from 863 men were analysed.

**Citation:** McEvoy A, Roberts P, Kailin Yap, Matson P (2015) The Relationship between the Halosperm Assay and Semen Analysis Performed According to the 4<sup>th</sup> and the 5<sup>th</sup> Editions of the World Health Organization Guidelines. Andrology 4: 127. doi:10.4172/2167-0250.1000127

Page 3 of 4

Semen Quality	WHO 4 <sup>th</sup> Edition		WHO 5 <sup>th</sup> Edition		Significance between 4 <sup>th</sup> and 5 <sup>th</sup> Editions	
	n	SDF (%)	n	SDF (%)	р	
Oligozoospermia (O)	31	23.3 ± 2.8 <sup>th</sup>	99	27.0 ± 1.7 <sup>I,o,p</sup>	NS	
Oligoteratozoospermia (OT)	77	27.6 ± 2.0 <sup>e,i</sup>	18	31.0 ± 4.4	NS	
Oligoasthenozoospermia (OA)	10	28.1 ± 6.4	21	$33.4 \pm 4.3^{m}$	NS	
Oligoasthenoteratozoospermia (OAT)	69	37.0 ± 2.6 <sup>d,g,h,i</sup>	13	46.6 ± 5.8 <sup>n,p</sup>	NS	
Normozoospermic (N)	385	17.5 ± 0.6 <sup>a,b,c,d,e,j</sup>	697	20.3 ± 0.6 <sup>j,k,l,m,n</sup>	0.001	
Normoteratozoospermia (NT)	203	21.8 ± 1.2 <sup>c,f,g</sup>	21	29.9 ± 4.9	NS	
Normoasthenozoospermia (NA)	45	28.0 ± 3.2 <sup>a</sup>	32	39.4 ± 4.6 <sup>k,o</sup>	NS	
Normoasthenoteratozoospermia (NAT)	85	30.7 ± 2.1 <sup>b,f</sup>	4	36.1 ± 9.6	NS	

Statistical differences within the same manual edition are represented with the same superscript and are significantly different (p<0.05). NS=Not significant.

Table 4: DNA Fragmentation levels (mean ± SEM) corresponding to semen parameters classified according to different WHO semen analysis editions (n=905).

Semen quality	Abnormal S		
	WHO 4 <sup>th</sup> Edition	WHO 5 <sup>th</sup> Edition	P value
Oligozoospermia (O)	6/31 (19.4%)	31/99 (31.3%)	0.100
Oligoteratozoospermia (OT)	22/77 (28.6%)	7/18 (38.9%)	0.195
Oligoasthenozoospermia (OA)	4/10 (40.0%)	10/21 (47.6%)	0.345
Oligoasthenoteratozoospermia (OAT)	37/69 (53.6%)	10/13 (76.9%)	0.060
Normozoospermic (N)	45/385 (11.7%)	112/697 (16.0%)	0.025*
Normoteratozoospermia (NT)	34/203 (16.8%)	9/21 (42.9%)	0.002*
Normoasthenozoospermia (NA)	13/45 (28.9%)	17/32 (53.1%)	0.016*
Normoasthenoteratozoospermia (NAT)	38/85 (44.7%)	3/4 (75.0%)	0.117

\*Significant association.

Table 5: Proportion of samples with abnormal DNA fragmentation levels (>30%) corresponding to WHO 4th Edition and WHO 5th Edition semen analysis criteria.

Samples classified as OAT by the 4<sup>th</sup> Edition semen analysis criteria had significantly higher DFLs than O (p<0.01) as did the samples classified by the 5<sup>th</sup> Edition (p<0.001). NA samples, classified under both 4<sup>th</sup> and 5<sup>th</sup> Edition criteria had significantly higher DFLs than N samples (p<0.001 and p<0.0001 respectively).

Comparing means of DFL for the various categories of semen quality is limited in that each group will have a mixture of samples with normal and clinically abnormal levels of DFL. Table 5 shows another way of looking at this by considering the proportion of semen samples that registered an abnormal sperm DFL (>30%) according to the corresponding semen analysis classification.

Samples recorded with sperm concentration, morphology and progressive motility levels outside of the WHO 4<sup>th</sup> and 5<sup>th</sup> Edition reference, revealed the highest proportion of samples with abnormal DFL (>30%), whilst the lowest proportion of samples with abnormal DFLs were shown to be within normal limits for all concentrations, morphology and progressive motility regardless of which manual's criteria were used.

## Discussion

Semen analysis is intended as a screening test to identify potential sub-fertility in men. As such, the test must be conducted under standard conditions so that the results of one man may be compared directly with others. This includes a standard period of sexual abstinence prior to production of the sample, as well as the use of standardized analytical procedures. To this end, the WHO have produced a series of manuals which include guidelines on the performance of semen analysis, and a series of reference ranges against which the samples may be judged. These manuals have undergone periodic revision and the last two editions, the 4<sup>th</sup> and 5<sup>th</sup>, are the ones in most frequent use these days.

This study has evaluated the relationships between semen quality as determined using both the WHO 4th and 5th Edition semen analysis criteria, and DFLs as identified by the Halosperm G2 test kit. The results reveal significantly higher DFLs in samples that have been classified as being abnormal compared with those with a semen analysis within normal parameters regardless of which edition of the WHO guidelines are used. Oligoasthenoteratozoospermic samples had the highest DFLs when compared to oligozoospermic, teratozoospermic and asthenozoospermic samples and it was evident that the proportion of samples with abnormal DFLs was higher when the WHO 5th Edition semen analysis criteria were applied compared to the 4th Edition criteria. No statistical difference was observed however between the specifically categorised semen defects when the two different guidelines were applied. Only samples with both abnormal motility and morphology, as scored using the 4th Edition criteria, showed a mean abnormal DFL. In contrast, all samples with some abnormality scored using 5th Edition semen analysis criteria revealed a mean abnormal DFL. The general finding that there is an inverse relationship between DFL and sperm morphology and motility, i.e. higher DFL when the proportion of sperm with normal morphology and motility is reduced, concurs with other reports [17,24-27].

Semen samples showed an inverse relationship between sperm concentration with DFL. This is in accord with Irvine et al., [25] who used WHO  $3^{rd}$  Edition criteria which has the same sperm concentration criteria as the  $4^{th}$  Edition [28]. Nevertheless, the proportion of samples with normal parameters according to the WHO  $4^{th}$  and  $5^{th}$  Editions but with DFLs >30% were 11.7% and 16% respectively. This is aligned with others' findings whereby approximately 15% of infertile men tested have semen within normal parameters [9,10]. Table 5 shows that a higher proportion of semen samples with normal sperm concentrations according to the 5th Edition but abnormalities of sperm

**Citation:** McEvoy A, Roberts P, Kailin Yap, Matson P (2015) The Relationship between the Halosperm Assay and Semen Analysis Performed According to the 4<sup>th</sup> and the 5<sup>th</sup> Editions of the World Health Organization Guidelines. Andrology 4: 127. doi:10.4172/2167-0250.1000127

morphology and/or motility have significantly elevated DFLs. The inclusion of a test of sperm DNA fragmentation is therefore important in providing additional information about the condition of the sperm. Men producing samples with abnormal DFLs may therefore approach assisted reproduction with a number of different strategies to help achieve a pregnancy, including the use of antioxidants [29], ICSI [16] or frequent ejaculation [30].

In summary, the present study has shown that there is an association between semen quality and DFL. The measurement of sperm DNA fragmentation does give further information on which to base decisions regarding future treatment. Care should also be taken as the reference range used in interpreting the semen analysis does influence the prevalence of abnormal DFL.

#### Acknowledgements

Laboratory staff at Fertility North, for their help in collecting and storing samples.

#### References

- 1. World Health Organisation (2010) WHO Laboratory Manual for the Examination and Processing of Human Semen. (5thedn), Geneva, Switzerland: WHO Press.
- Esteves SC, Zini A, Aziz N, Alvarez JG, Sabanegh Jr. ES, et al. (2012) Critical appraisal of World Health Organization's new reference values for human semen characteristics and effect on diagnosis and treatment of subfertile men. Urology 79: 16-22.
- Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HWG, et al. (2010) World Health Organization reference values for human semen characteristics. Hum Reprod Update 16: 231-245.
- Catanzariti F, Cantoro U, Lacetera V, Muzzonigro G, Polito M (2013) Comparison between WHO (World Health Organization) 2010 and WHO 1999 parameters for semen analysis – interpretation of 529 consecutive samples. Archivio Italiano di Urologia e Andrologia 85: 125-129.
- Menkveld R, Holleboom CAG, Rhemrev JPT (2011) Measurement and significance of sperm morphology. Asian Journal of Andrology 13: 59-68.
- Lu JC, Zhang HY, Hu YA, Huang YF, Lu NQ (2010) A survey on the status of semen analysis in 118 laboratories in China. Asian Journal of Andrology 12: 104-110.
- De Jonge C (2012) Semen analysis: looking for an upgrade in class. Fertil Steril 97: 260-266.
- Lewis SE, Agbaje I, Alvarez J (2008) Sperm DNA tests as useful adjuncts to semen analysis. Syst Biol Reprod Med 54: 111-125.
- Omran HM, Bakhiet M, Dashti MG (2013) DNA integrity is a critical molecular indicator for the assessment of male infertility. Mol Med Report 7: 1631-1635.
- Schulte RT, Ohl DA, Sigman M, Smith GD (2010) Sperm DNA damage in male infertility: Etiologies, assays, and outcomes. J Assist Reprod Genet 27: 3-12.
- Chohan KR, Griffin JT, Lafromboise M, De Jonge CJ, Carrell DT (2006) Comparison of chromatin assays for DNA fragmentation evaluation in human sperm. J Androl 27: 53-59.
- Shamsi MB, Imam SN, Dada R (2011) Sperm DNA integrity assays: Diagnostic and prognostic challenges and implications in management of infertility. J Assist Reprod Genet 28: 1073-1085.
- Tamburrino L, Marchiani S, Montoya M, Elia Marino F, Natali I, et al. (2012) Mechanisms and clinical correlates of sperm DNA damage. Asian Journal of Andrology 14: 24-31.
- 14. Zini A (2011) Are sperm chromatin and DNA defects relevant in the clinic? Syst Biol Reprod Med 57: 78.
- Bakos HW, Thompson JG, Feil D, Lane M (2007) Sperm DNA damage is associated with assisted reproductive technology pregnancy. Int J Androl 31: 518-526.
- 16. Lewis SEM, Aitken RJ, Conner SJ, De Iuliis G, Evenson D, et al. (2013) The impact of sperm DNA damage in assisted conception and beyond: recent

advances in diagnosis and treatment. Reproductive BioMedicine Online 27: 325-337.

- Mangiarini A, Paffoni A, Restelli L, Ferrari S, Guarneri C, et al. (2013) Specific sperm defects are differentially correlated with DNA fragmentation in both normozoospermic and teratozoospermic subjects. Andrology 1: 838-844.
- Lewis SEM (2013) The place of sperm DNA fragmentation testing in current day fertility management. Middle East Fertility Society Journal 18: 78-82.
- Sharma RK, Said T, Agarwal A (2004) Sperm DNA damage and its clinical relevance in assessing reproductive outcome. Asian Journal of Andrology 6: 139-148.
- Venkatesh S, Singh A, Shamsi MB, Thilagavathi J, Kumar R, et al. (2011) Clinical significance of sperm DNA damage threshold value in the assessment of male infertility. Reprod Sci 18: 1005-1013.
- Fernández JL, Muriel L, Goyanes V, Segrelles E, Gosálvez J, et al. (2005) Halosperm 
   B is an easy, available, and cost-effective alternative for determining sperm DNA fragmentation. Fertil Steril 84: 860.
- World Health Organisation (1999) WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucas Interaction. (4thedn), Cambridge, UK: Cambridge University Press.
- McEvoy A, Roberts P, Yap K, Matson P (2014) Development of a simplified method of human semen storage for the testing of sperm DNA fragmentation using the Halosperm G2 test kit. Fertil Steril 102: 981-988.
- 24. Lopes S, Sun J, Jurisicova A, Meriano J, Casper RF (1998) Sperm deoxyribonucleic acid fragmentation is increased in poor-quality semen samples and correlates with failed fertilization in intracytoplasmic sperm injection. Fertil Steril 69: 528-532.
- Irvine DS, Twigg JP, Gordon EL, Fulton N, Milne PA, et al. (2000) DNA integrity in human spermatozoa: relationships with semen quality. J Androl 21: 33-44.
- Peluso G, Palmieri A, Cozza PP, Morrone G, Verze P, et al. (2013) The study of spermatic DNA fragmentation and sperm motility in infertile subjects. Archivio Italiano di Urologia e Andrologia 85: 8-13.
- 27. Velez de la Calle JF, Muller A, Walschaerts M, Clavere JL, Jimenez C, et al. (2008) Sperm deoxyribonucleic acid fragmentation as assessed by the sperm chromatin dispersion test in assisted reproductive technology programs: results of a large prospective multicenter study. Fertil Steril 90: 1792-1799.
- Esteves SC, Miyaoka R, Agarwal A (2011) An update on the clinical assessment of the infertile male. Clinics 66: 691-700.
- Tunc O, Thompson J, Tremellen K (2009) Improvement in sperm DNA quality using an oral antioxidant therapy. Reprod Biomed Online 18: 761-768.
- Gosalvez J, Gonzalez-Martinez M, Lopez-Femandez C, Fernandez JL (2013) Shorter abstinence decreases sperm deoxyribonucleic acid fragmentation in ejaculate. Fertil Steril 96: 1083-1086.

**Citation:** McEvoy A, Roberts P, Kailin Yap, Matson P (2015) The Relationship between the Halosperm Assay and Semen Analysis Performed According to the 4<sup>th</sup> and the 5<sup>th</sup> Editions of the World Health Organization Guidelines. Andrology 4: 127. doi:10.4172/2167-0250.1000127